Networks in Neurology: New Agents and Strategies for Migraine
One out of six US adults suffer from migraines and yet, until recently, management has been reliant on treatments designed for other conditions that had some consequential success. Fortunately, this long-standing paradigm has not only ended but has accelerated in the opposite direction. The rapid acquisition of new therapies has created a near impossible amount of information to parse out efficiently. This curriculum, originally presented as a small group interactive learning program through RealCME’s Gather-Ed platform, is designed to help participants improve their migraine management skills by distilling what information is most relevant in the evolving world and what it means for patients. The activity features an in-depth interview with a renowned headache specialist, Dr Shivang Joshi, regarding the appropriate application of recent advances in headache medicine. Throughout the activity, Dr Joshi reviews his own management approaches for a variety of scenarios relevant to modern practice as well as those of the other experts involved in this project.
This activity is intended for neurologists involved in the care of patients with migraine and other headache disorders.
- Compare and contrast your management approaches for patients with diverse presentations of migraine to physicians that specialize in the care of the disease and affirm or modify your planned decision-making accordingly.
- Recognize the indications for the use of preventive treatment in patients suffering from episodic and chronic migraine to ensure its timely consideration by these individuals.
- Review the therapeutic profiles associated with FDA-approved calcitonin gene-related peptide (CGRP) monoclonal antibodies for the prevention of episodic and chronic migraine and discern how and for whom these agents can be appropriately prescribed.
- Describe the mechanisms of action and clinical profiles of recently approved abortive medications for the management of migraine and identify individuals that may be candidates for these therapies.
Shivang Joshi, MD, MPH, RPh (Chair)
Associate Professor of Clinical Pharmacy Practice
University of Buffalo School of Pharmacy
DENT Neurological Institute
Amherst, New York
Ryan Smith, DO (Moderator)
Assistant Professor of Neurology
Idaho College of Osteopathic Medicine
University of Washington
Director of Headache Medicine
St Luke's Health System
Jessica Ailani, MD
Professor of Neurology
Georgetown University Hospital
Wade Cooper, DO
Clinical Associate Professor of Neurology
Clinical Associate Professor in Anesthesiology
Director, Headache & Neuropathic Pain
University of Michigan School of Medicine
Ann Arbor, Michigan
Ira Turner, MD
The Center for Headache Care and Research
at Island Neurological Associates, P.C.
Plainview, New York
This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC.
Conflict of Interest Disclosure Policy
Planners' and Managers' Disclosure
- Consulting fees: Allergan/Abbvie, Axsome Therapeutics, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Satsuma Pharmaceuticals Inc., Teva Pharmaceuticals, Theranica
- Contracted research: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Satsuma Pharmaceuticals Inc., Zosano Pharma
- Fees for Non-CME/CE Services: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Teva Pharmaceuticals
- Stock options: Ctrl M Health
- Consulting fees: Amgen, Dolor Technologies, Lilly, Lundbeck, Teva Pharmaceuticals, Theranica
- Ownership interest: Dolor Technologies
- Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Teva Pharmaceuticals
- Consulting fees: Allergan
- Fees for Non-CME/CE Services: Allergan, Amgen, Lilly, Teva
- Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Novartis Pharmaceuticals Corp., Revance Therapeutics Inc., Teva Pharmaceuticals, Theranica
- Contracted research: Allergan, Lilly, Teva Pharmaceuticals, Theranica
Disclosure of Unlabeled Use
- 1.25 AMA PRA Category 1 Credit™